Application of vaccinia virus inflammatory rabbit skin extract in treatment of Alzheimer's disease
Patent Information
- Application Number
- CN202280093636.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2022-04-01
- Publication Date
- 2024-11-26
AI Technical Summary
It is difficult to effectively prevent or treat Alzheimer's disease with existing technology, especially the neurological damage caused by β-amyloid plaque deposition in the brain, glial cell inflammatory response, and expression of inflammatory factors.
The extract of rabbit skin caused by vaccinia virus inflammation can be used as a single active ingredient or pharmaceutical composition to prevent or treat Alzheimer's disease by reducing β-amyloid plaque deposition, glial cell inflammatory response and inflammatory factor expression in the brain. silent disease.
Significantly slows down cognitive dysfunction in Alzheimer's disease model mice, reduces Aβ load and microglial inflammatory response, and improves or restores cognitive function.
Smart Images

Figure CN119031925A_ABST
Abstract
Description
Use of extract from rabbit skin inflamed by vaccinia virus in treating Alzheimer's disease Field of the Invention
[0001] The present invention belongs to the field of medicine. Specifically, the present invention relates to novel therapeutic uses of extracts from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the medical use of extracts from rabbit skin inflamed by vaccinia virus for treating Alzheimer's disease. Background Art
[0002] Alzheimer's disease (AD) is a slowly progressive disease that worsens over time, directly caused by the gradual degeneration of neurons. The most common early symptom is loss of short-term memory. As the disease progresses, symptoms may gradually appear, including language impairment, disorientation, emotional instability, loss of motivation, inability to care for oneself, and numerous behavioral problems. As the condition worsens, patients often become disconnected from their families and society, gradually lose physical function, and ultimately die.
[0003] In Alzheimer's disease, the hippocampus is the first area to be damaged, with symptoms including memory loss and loss of orientation (see Yangling Mu et al., Adult hippocampal neurogenesis and its role in Alzheimer's disease, Mol Neurodegener, 2011; 6:85). The progression of Alzheimer's disease is associated with the deposition of β-amyloid (Aβ) plaques and tau protein in the brain (see Clive Ballard et al., Alzheimer's disease, The Lancet. 2011 March, 377(9770):1019–1031). Recent studies have found that neuroinflammation or microglial activation is involved in the spread of tau protein tangles in the neocortex in Alzheimer's disease, which in turn leads to the occurrence of cognitive dysfunction in Alzheimer's patients (see Tharick A. Pascoal et al., Microglial activation and tau propagate jointly across Braak stages, Nature Medicine, 27, pages 1592–1599 (2021 August)). Microglial activation is part of the human brain's immune response and is a key factor associated with the development of Alzheimer's disease. Excessive activation of microglia is not only an inflammatory epiphenomenon, but also a key upstream mechanism that is crucial to the development of AD. Studies have also found that neuroinflammation and certain inflammatory cytokines are involved in the pathology of AD (see Rishika Dhapola et al., Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer's disease, Inflammopharmacology volume 29, pages 1669–1681 (2021 November)). Therefore, reducing Aβ plaque deposition, alleviating neuroinflammation, and inhibiting microglial activation can be considered as effective means to treat or alleviate AD.
[0004] There is a need in the art for drugs that are effective in treating Alzheimer's disease.
[0005] Vaccinia virus-inflamed rabbit skin extract is an active substance extracted from the skin of rabbits that have been inflamed after being vaccinated with vaccinia virus. This vaccinia virus-inflamed rabbit skin extract is commercially available under the trade name Lepalvir for pain treatment. The extract has been shown to be clinically safe and has no significant side effects. In addition, WO 2020 / 211009 discloses the use of vaccinia virus-inflamed rabbit skin extract for treating hematopoietic system damage; WO 2020 / 248240 discloses the use of vaccinia virus-inflamed rabbit skin extract for treating cancer, and their entire contents are incorporated herein by reference.
[0006] Summary of the Invention
[0007] The present invention aims to provide a drug for preventing, alleviating or treating Alzheimer's disease. The technical problem of the present invention is solved by providing a vaccinia virus-induced inflamed rabbit skin extract, preferably Lizaitin.
[0008] In summary, the inventors found that extracts from rabbit skin inflamed by vaccinia virus can effectively prevent, treat or alleviate Alzheimer's disease.
[0009] In one aspect, the present invention relates to the use of an extract of rabbit skin inflamed by vaccinia virus for the preparation of a medicament for preventing or treating Alzheimer's disease in a patient. In one aspect, the present invention relates to an extract of rabbit skin inflamed by vaccinia virus for use in preventing or treating Alzheimer's disease in a patient. In one aspect, the present invention relates to a method of preventing or treating Alzheimer's disease in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of an extract of rabbit skin inflamed by vaccinia virus.
[0010] In one aspect, a vaccinia virus-inflamed rabbit skin extract or a drug is used to protect brain neurological function or alleviate brain neurological function damage in patients with Alzheimer's disease. Brain neurological function damage can be caused by the deposition of beta-amyloid protein (Aβ) plaques in the brain, glial cell inflammatory response, and / or increased expression or level of inflammatory factors.
[0011] In one aspect, prevention or treatment of Alzheimer's disease is achieved by alleviating or reducing β-amyloid plaque deposition, glial cell inflammatory response, or the expression or level of inflammatory factors in the brain.
[0012] In one aspect, the present invention relates to the use of a vaccinia virus-inflamed rabbit skin extract in the preparation of a method for protecting brain neurological function or alleviating brain neurological function damage in patients with Alzheimer's disease. In one aspect, the present invention relates to a vaccinia virus-inflamed rabbit skin extract for use in protecting brain neurological function or alleviating brain neurological function damage in patients with Alzheimer's disease. In one aspect, the present invention relates to a method for protecting brain neurological function or alleviating brain neurological function damage in patients with Alzheimer's disease, the method comprising administering a therapeutically effective amount of a vaccinia virus-inflamed rabbit skin extract to the patient.
[0013] In one aspect, protecting brain neurological function or alleviating brain neurological function damage in patients with Alzheimer's disease is achieved by alleviating or reducing β-amyloid plaque deposition, glial cell inflammatory response, or the expression or level of inflammatory factors in the brain.
[0014] In one aspect, the present invention relates to the use of an extract from rabbit skin inflamed by vaccinia virus for the preparation of a medicament for alleviating or reducing the deposition of β-amyloid plaques in the brain of a patient suffering from Alzheimer's disease. In one aspect, the present invention relates to an extract from rabbit skin inflamed by vaccinia virus for alleviating or reducing the deposition of β-amyloid plaques in the brain of a patient suffering from Alzheimer's disease. In one aspect, the present invention relates to a method for alleviating or reducing the deposition of β-amyloid plaques in the brain of a patient suffering from Alzheimer's disease, the method comprising administering a therapeutically effective amount of an extract from rabbit skin inflamed by vaccinia virus to the patient.
[0015] In one aspect, beta-amyloid plaque deposition can occur in the hippocampus or cortex of the brain.
[0016] In one aspect, the present invention relates to the use of a vaccinia virus-inflamed rabbit skin extract in the preparation of a medicament for alleviating or reducing glial inflammatory responses in the brain of a patient suffering from Alzheimer's disease. In one aspect, the present invention relates to a vaccinia virus-inflamed rabbit skin extract for alleviating or reducing glial inflammatory responses in the brain of a patient suffering from Alzheimer's disease. In one aspect, the present invention relates to a method for alleviating or reducing glial inflammatory responses in the brain of a patient suffering from Alzheimer's disease, the method comprising administering a therapeutically effective amount of a vaccinia virus-inflamed rabbit skin extract to the patient.
[0017] Glial cells, also known as neuroglial cells, can be selected from astrocytes or microglia, preferably microglia. Glial cells can be cortical glial cells in the brain or hippocampal glial cells. The extract of the present invention can reduce or alleviate abnormalities or activation of cortical glial cells or hippocampal glial cells in the brain, thereby achieving prevention or treatment. Glial inflammatory reactions can be associated with or caused by abnormalities or activation of glial cells.
[0018] In one aspect, the present invention relates to the use of a vaccinia virus-inflamed rabbit skin extract in the preparation of a medicament for alleviating or reducing the expression or level of inflammatory factors in the brain of a patient suffering from Alzheimer's disease. In one aspect, the present invention relates to a vaccinia virus-inflamed rabbit skin extract for alleviating or reducing the expression or level of inflammatory factors in the brain of a patient suffering from Alzheimer's disease. In one aspect, the present invention relates to a method for alleviating or reducing the expression or level of inflammatory factors in the brain of a patient suffering from Alzheimer's disease, the method comprising administering a therapeutically effective amount of a vaccinia virus-inflamed rabbit skin extract to the patient.
[0019] Inflammatory factors primarily refer to inflammatory cytokines or proinflammatory cytokines, which can be selected from interleukin-1β (IL-1β), interleukin-6 (IL-6), or tumor necrosis factor-α (TNF-α). Inflammatory factors can be inflammatory factors in the cerebral cortex or hippocampus. Therefore, the extract of the present invention can be used to alleviate or reduce the expression or level of inflammatory factors in the cortex or hippocampus of patients with Alzheimer's disease.
[0020] In one aspect, a vaccinia virus-inflamed rabbit skin extract is used to prepare a medicament for improving, enhancing, or restoring cognitive function or cognitive ability in patients with Alzheimer's disease. In one aspect, the present invention relates to a vaccinia virus-inflamed rabbit skin extract for improving, enhancing, or restoring cognitive function or cognitive ability in patients with Alzheimer's disease. In one aspect, the present invention relates to a method for improving, enhancing, or restoring cognitive function or cognitive ability in patients with Alzheimer's disease, comprising administering a therapeutically effective amount of a vaccinia virus-inflamed rabbit skin extract to the patient. Cognitive function or cognitive ability may include perception, logical thinking, memory, language, learning, emotional control, social skills, or attention.
[0021] In one aspect, a vaccinia virus-inflamed rabbit skin extract can be used as the sole active ingredient in the treatment of Alzheimer's disease. In this aspect, the vaccinia virus-inflamed rabbit skin extract can be used as the sole active ingredient in the preparation of a medicament for treating Alzheimer's disease, or for protecting brain neurological function or alleviating brain neurological function damage in patients with Alzheimer's disease, or for alleviating or reducing β-amyloid plaque deposition in the brains of patients with Alzheimer's disease, or for alleviating or reducing glial cell inflammatory responses in the brains of patients with Alzheimer's disease, or for alleviating or reducing the expression or level of inflammatory factors in the brains of patients with Alzheimer's disease. In the treatment methods of the present invention, the vaccinia virus-inflamed rabbit skin extract can be administered to the patient as the sole active ingredient. "Sole active ingredient" means that the vaccinia virus-inflamed rabbit skin extract is not used, administered to a patient, or prepared in conjunction with other Alzheimer's disease treatment drugs. In one aspect, the present invention relates to a pharmaceutical composition comprising a vaccinia virus-inflamed rabbit skin extract and, optionally, a pharmaceutically acceptable carrier, excipient, or vehicle. In one aspect of the present invention, the pharmaceutically acceptable carrier, excipient or vehicle is one that is used to prepare the drug into an oral preparation or injection. In one aspect, the vaccinia virus-inflamed rabbit skin extract is prepared into an oral preparation or injection, preferably an intramuscular injection or an intravenous injection. In one aspect, the vaccinia virus-inflamed rabbit skin extract is Lizaitin. Accordingly, the present invention also relates to the use of the pharmaceutical composition for treating Alzheimer's disease, or protecting brain nerve function or alleviating brain nerve function damage in patients with Alzheimer's disease, or alleviating or reducing β-amyloid plaque deposition in the brain of patients with Alzheimer's disease, or alleviating or reducing glial cell inflammatory response in the brain of patients with Alzheimer's disease, or alleviating or reducing the expression or level of inflammatory factors in the brain of patients with Alzheimer's disease. The present invention also relates to the use of the vaccinia virus-inflamed rabbit skin extract in the preparation of the pharmaceutical composition.
[0022] In one aspect, the vaccinia virus-inflamed rabbit skin extract is Lizaitin.
[0023] In one aspect, the vaccinia virus-inflamed rabbit skin extract is formulated into an oral preparation or an injection, preferably an intramuscular injection or an intravenous injection.
[0024] In one aspect, the patient is a mammal, preferably a human.
[0025] In one aspect, the vaccinia virus-inflamed rabbit skin extract is administered to a patient, such as a human, in an amount of 0.05 U / kg to 50 U / kg, preferably 0.1 U / kg to 10 U / kg, more preferably 0.5 U / kg to 5 U / kg.
[0026] In one aspect, the prepared medicament comprises 3U to 3000U, preferably 6U to 600U, more preferably 30U to 300U of the vaccinia virus-induced inflamed rabbit skin extract.
[0027] In one aspect, the vaccinia virus-induced inflamed rabbit skin extract (preferably Lipofectamine) is administered to a patient, preferably a human, in an amount of 0.05 U / kg to 50 U / kg, preferably 0.1 U / kg to 10 U / kg, more preferably 0.5 U / kg to 5 U / kg. For example, the vaccinia virus-induced inflamed rabbit skin extract is administered to a patient, preferably a human, in an amount selected from the group consisting of: 0.05 U / kg, 0.06 U / kg, 0.07 U / kg, 0.08 U / kg, 0.09 U / kg, 0.1 U / kg, 0.2 U / kg, 0.3 U / kg, 0.4 U / kg, 0.5 U / kg, 0.6 U / kg, 0.7 U / kg, 0.8 U / kg, 0.9 U / kg, 1 U / kg, 1.5 U / kg, 2 U / kg, 2.5 U / kg, 3 U / kg, 3.1 U / kg, 3.2 U / kg, 3.3 U / kg, 3.4 U / kg, 3.5 U / kg, 3.6 U / kg, 3.7 U / kg, 3.8 U / kg, 3.9 U / kg, 4 U / kg, 4.5 U / kg, 5 U / kg, 5.5 U / kg, 6 U / kg, 6.5U / kg, 7U / kg, 7.5U / kg, 8U / kg, 8.5U / kg, 9U / kg, 9.5U / kg, 10U / kg, 11U / kg, 12U / kg, 13U / kg, 14U / kg, 15U / kg, 16U / kg, 17U / kg, 18U / kg, 19U / kg, 20U / kg, 25U / kg, 30U / kg, 35U / kg, 40U / kg, 45U / kg, 50U / kg and the scope with these numbers as boundary. Those skilled in the art know that for dosage, people's dosage (U / kg or mg / kg)=mouse's dosage (U / kg or mg / kg) / 12.3;Or people's dosage (U / kg or mg / kg)=mouse's dosage (U / kg or mg / kg) × 0.08.The above dosage can be the effective amount for treating the above-mentioned disease in patient. In one aspect, the extract of vaccinia virus-inflamed rabbit skin is administered by injection at the above dosage, such as intramuscular injection or intravenous injection.
[0028] In one aspect of the present invention, the prepared medicament or pharmaceutical composition comprises 3U to 3000U, preferably 6U to 600U, more preferably 30U to 300U of vaccinia virus-induced rabbit skin extract. The medicament or pharmaceutical composition is used to administer to humans, such as adults. The average weight of an adult is, for example, 60kg. Accordingly, the amount of vaccinia virus-induced rabbit skin extract contained in the medicament prepared by the present invention is, for example, 3U, 4U, 5U, 6U, 7U, 8U, 9U, 10U, 15U, 20U, 25U, 30U, 35U, 40U, 42U, 44U, 45U, 46U, 47U, 48U, 49U, 50U, 55U, 60U, 65U, 70U, 80U, 90U, 100U, 120U, 150U, In one aspect, the medicine or pharmaceutical composition is prepared as an injection, for example, an intramuscular injection or an intravenous injection. In one aspect, the medicine or injection is an indivisible fixed dose. In one aspect, the medicine or injection can not be divided into smaller doses within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days or 7 days. In one aspect, the drug or injection is administered only once within 1 day, 2 days, 3 days, 4 days, 5 days, 6 days or 7 days.
[0029] In one aspect, the patient is administered an extract of vaccinia virus-inflamed rabbit skin every 6-72 hours, preferably 12-48 hours, more preferably 24-36 hours, more preferably 24 hours.
[0030] In one aspect, the regimen of administration to the patient is three times a day, twice a day, once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, once a month. For example, the extract of the present invention can be administered to the patient once a day.
[0031] In one aspect, the extract of the present invention is administered to the patient for at least 24 months, at least 12 months, at least 6 months, at least 2 months, at least 1 month, at least 3 weeks, at least 2 weeks, at least 10 days, at least 7 days, at least 5 days, at least 2 days, or at least 1 day.
[0032] The "extract from rabbit skin inflamed by vaccinia virus" described herein refers to an extract containing active ingredients extracted from inflamed rabbit skin inoculated with vaccinia virus, for example, through extraction, purification, and refinement processes. This extract is typically a yellow or light yellow liquid, but can also be made into a solid by drying. Injectable solutions of this vaccinia virus-inflamed rabbit skin extract are commercially available under the trade name Lepalvir. The vaccinia virus-inflamed rabbit skin extract of the present invention may contain peptides. For example, it has been found that the extract may contain naturally occurring peptides (i.e., not additionally added peptides). The peptides may be short peptides. Therefore, in this aspect, the vaccinia virus-inflamed rabbit skin extract of the present invention may not be a non-protein extract.
[0033] In the preparation of the extract of the present invention, the preparation method comprises extracting rabbit skin fragments that have become inflamed after vaccinia virus inoculation with an aqueous phenol solution, wherein the extraction is preferably performed using an aqueous phenol solution having a phenol concentration of about 1%-10%, preferably about 2%-5%, more preferably about 2% or about 3%, at a temperature below about 12° C., for example, about 0-10° C., preferably about 2-8° C., more preferably about 3-6° C., and even more preferably about 4° C. Furthermore, the preparation method further comprises adsorbing the extract treated with the aqueous phenol solution with an adsorbent (e.g., activated carbon) and desorbing the extract under alkaline conditions, wherein the adsorption is preferably performed under acidic conditions (e.g., about pH 3-6, more preferably about pH 4-5, and even more preferably about pH 4.5), and the alkaline conditions for desorption are about pH 9-12, preferably about pH 10 or pH 11.
[0034] In one aspect, the vaccinia virus-induced rabbit skin extract or vaccinia virus extract can be prepared by a method comprising the following steps:
[0035] (1) collecting inflamed rabbit skin after inoculation with vaccinia virus, fragmenting the rabbit skin, and extracting with an extraction solvent to obtain solution A;
[0036] (2) treating solution A with acid and heating to obtain solution B;
[0037] (3) treating solution B with alkali and heat to obtain solution C;
[0038] (4) adsorbing and filtering solution C under acidic conditions, and desorbing under alkaline conditions to obtain solution D;
[0039] (5) neutralizing and heating solution D to obtain solution E;
[0040] (6) concentrating solution E to obtain the extract; and
[0041] (7) Optionally, the extract is mixed with a pharmaceutically acceptable carrier, adjuvant or vehicle.
[0042] In one aspect, in step (1), a rabbit is inoculated with vaccinia virus, the pox-affected skin is collected, the skin is fragmented, and a phenol aqueous solution is added. The fragmented skin is soaked at a temperature below about 12° C. (e.g., about 0-10° C., preferably about 2-8° C., more preferably about 3-6° C., and more preferably about 4° C.) for at least about 12 hours (e.g., about 24-90 hours, preferably about 48-72 hours, and more preferably about 70 or about 72 hours). The supernatant is centrifuged and filtered to obtain solution A. The phenol aqueous solution has a phenol concentration of about 1% to 10%, preferably about 2% to 5%, and more preferably about 2% or about 3%.
[0043] In one aspect, in step (2), solution A is adjusted to acidity (e.g., about pH 4-6, more preferably about pH 4.5-5.5, more preferably about pH 5) with an acid (e.g., hydrochloric acid), heated (e.g., at about 90-100° C., preferably about 95° C. for at least about 10 minutes, e.g., about 20-50 minutes, preferably about 30-40 minutes), optionally cooled (e.g., to below about 50° C., preferably below about 30° C.), then centrifuged to obtain a supernatant, which is then filtered to obtain solution B. Step (2) can be performed under a nitrogen atmosphere.
[0044] In one aspect, in step (3), solution B is adjusted to alkaline (e.g., about pH 8-10, more preferably about pH 8.5-9.5, more preferably about pH 9 or about pH 9.2) with a base (e.g., sodium hydroxide), heated (e.g., at about 90-100° C., preferably about 95° C. for at least 10 minutes, e.g., about 30-50 minutes, preferably about 30-40 minutes), optionally cooled (e.g., to below about 50° C., preferably below about 30° C.), and filtered to obtain solution C. Step (3) can be carried out under a nitrogen environment.
[0045] In one aspect, in step (4), solution C is adjusted to acidic (e.g., pH 3-6, more preferably pH 4-5, more preferably pH 4.5) with an acid (e.g., hydrochloric acid), an adsorbent (e.g., activated carbon) is added thereto for soaking (e.g., under stirring for at least about 1 hour, preferably about 2-10 hours, more preferably about 4 hours), after which the solution is removed and the adsorbent containing the active ingredient is collected. Subsequently, the adsorbent is added to an eluent (e.g., water), and the pH is adjusted to alkaline (e.g., pH 9-12, preferably about pH 10 or pH 11) with an alkali (e.g., sodium hydroxide) to separate the active ingredient from the adsorbent (e.g., stirring for at least about 1 hour, preferably 2-10 hours, more preferably 4 hours, followed by filtration, and then washing the adsorbent with water) to obtain solution D. Step (4) can be performed under a nitrogen environment.
[0046] In one aspect, in step (5), solution D is neutralized to a weak acidity (eg, about pH 5.5-6.6, preferably about pH 6) with an acid (eg, hydrochloric acid) to obtain solution E. Preferably, step (5) can be performed under sterile conditions.
[0047] In one aspect, in step (6), solution E is concentrated (e.g., concentrated under reduced pressure, preferably concentrated by evaporation under reduced pressure, e.g., at about 50° C. to 70° C., preferably at about 54° C. to 56° C.), and then filtered to obtain an extract containing the active ingredient. Step (6) can be performed under a nitrogen atmosphere.
[0048] In one aspect, the patient is a mammal. In one aspect, the patient is a human, such as a middle-aged or elderly person, preferably an elderly person. A middle-aged person can be a person between 40 and 59 years old or a person between 45 and 59 years old. An elderly person can be a person over 60, over 65, over 70, over 75, or over 80 years old.
[0049] Those skilled in the art will appreciate that the extracts of the present invention can also be obtained by inoculating other animal tissues with vaccinia virus. For example, extracts from inflamed tissue inoculated with vaccinia virus can be used in the present invention. The tissue can be from a mammal, including companion animals, experimental animals, and livestock, such as rabbits, cattle, horses, sheep, goats, monkeys, mice, and pigs. The tissue can be skin.
[0050] BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 shows the effects of different doses of levofloxacin on short-term learning and memory, conditioned fear memory, and social ability in APP / PS1 mice. (A) Percentage of time mice spent in the novel arm of a Y-maze test; (B) Number of times mice spent in the novel arm of a Y-maze test; (C) Cognitive index of mice in the novel object recognition test; (D) Percentage of time spent freezing in the conditioned fear memory test; (E) Percentage of time mice spent in the empty and Stranger-1 chambers in the social preference test; (F) Percentage of time mice spent in the Stranger-1 and Stranger-2 chambers in the social memory test. Data were analyzed using one-way analysis of variance with multiple comparisons (AD) and two-way analysis of variance (EF). P < 0.05 was considered statistically significant. Data are presented as mean ± standard error. Black circles in the statistical graphs represent the number of mice. N = 11-13 per group (due to local injuries caused by fighting between male mice during housing, mice with poor behavioral condition were removed). % of time spent in the novel arm: percentage of time spent in the novel arm; number of entries into the novel arm: number of entries into the novel arm; recognition index: recognition index; freezing: freezing; time spent: time spent.
[0052] Figure 2 shows the effects of different doses of lisdex on Aβ deposition in APP / PS1 mice. (A) Immunofluorescence staining for thioflavin-positive plaques in the cerebral cortex and hippocampus of mice after administration of different doses of lisdex. (BC) Quantification of thioflavin-positive Aβ plaques in the cortex and hippocampus of mice treated with different doses of lisdex. (D) Immunofluorescence staining for 6E10-positive plaques in the cerebral cortex and hippocampus of mice treated with different doses of lisdex. (EF) Quantification of 6E10-positive plaques in the cortex and hippocampus of mice treated with different doses of lisdex. Data were statistically analyzed by one-way analysis of variance with multiple comparisons (BC, EF). p < 0.05 was considered statistically significant. Data are presented as mean ± standard error. Black circles in the statistical graphs represent the number of mice; n = 4-5 per group. Thioflavine-S: Thioflavine S; Aβ plaques area in the cortex: Aβ plaque area in the cortex; Aβ plaques area in the hippocampus: Aβ plaque area in the hippocampus; 6E10 positive area in the cortex: 6E10 positive area in the cortex; 6E10 positive area in the hippocampus: 6E10 positive area in the hippocampus.
[0053] Figure 3 shows the effects of different doses of lisdex on glial cell activation surrounding Aβ plaques in the cortex of APP / PS1 mice. (A) Immunofluorescence staining of the astrocyte marker GFAP and the microglial marker Iba-1 in the cortex of mice treated with different doses of lisdex. (BC) Percentage of GFAP- and Iba1-positive areas in the cortex of mice treated with different doses of lisdex. Data were statistically analyzed by one-way analysis of variance with multiple comparison test (BC). p < 0.05 was considered statistically significant. Data are presented as mean ± standard error. Black circles in the statistical graphs represent the number of mice, n = 4-5 per group. GFAP positive area: GFAP-positive area; Iba-1 positive area: Iba-1-positive area.
[0054] Figure 4 shows the effects of different doses of lisdex on glial cell activation surrounding Aβ plaques in the hippocampus of APP / PS1 mice. (A) Immunofluorescence staining of the astrocyte marker GFAP and the microglial marker Iba-1 in the hippocampus of mice treated with different doses of lisdex. (BC) Percentage of GFAP- and Iba1-positive areas in the hippocampus of mice treated with different doses of lisdex. Data were statistically analyzed by one-way analysis of variance with multiple comparison test (BC). p < 0.05 was considered statistically significant. Data are presented as mean ± standard error. Black circles in the statistical graphs represent the number of mice, n = 4-5 per group. GFAP positive area: GFAP-positive area; Iba-1 positive area: Iba-1-positive area.
[0055] Figure 5 shows the effects of different doses of Lizaishi on the inflammatory factors IL-1β, IL-6 and TNF-α in the cerebral cortex and hippocampus of APP / PS1 mice. (AC) ELISA was used to detect the expression of IL-1β, IL-6 and TNF-α in the cortex of mice after administration of different doses of Lizaishi. (DF) ELISA was used to detect the expression of IL-1β, IL-6 and TNF-α in the hippocampus of mice after administration of Lizaishi. The data were statistically analyzed by one-way analysis of variance with multiple comparison test (AF). p<0.05 was considered statistically significant. The data are presented as mean ± standard error. The black circles in the statistical graphs represent the number of mice, n=5 per group. IL-1β levels in the cortex: IL-1β levels in the cortex; IL-6 levels in the cortex: IL-6 levels in the cortex; TNFα levels in the cortex: TNFα levels in the cortex; IL-1β levels in the hippocampus: IL-1β levels in the hippocampus; IL-6 levels in the hippocampus: IL-6 levels in the hippocampus; TNFα levels in the hippocampus: TNFα levels in the hippocampus. DETAILED DESCRIPTION
[0056] Unless otherwise indicated, all scientific terms used herein have the same meaning as those generally understood by those skilled in the art. Exemplary methods and materials are described below, and their equivalents may be used. All publications and other references mentioned herein are incorporated herein by reference in their entirety.
[0057] The following examples are provided to further illustrate the present invention. The following examples are not intended to limit the scope of the present invention for any reason.
[0058] Example
[0059] Example 1 - Study on the neuroprotective effect of Lizaitin on the Alzheimer's disease model animal APP / PS1 mice I. Research methods
[0060] 1. Lizaishi administration
[0061] Seventy-five five-month-old APP / PS1 male mice on a C57BL / 6 background were treated with 80 μL of saline and an equal volume of Lipofectamine (5, 10, 20, and 40 U / kg) at different doses, intraperitoneally injected daily at the same time for four weeks. Each group received a total intraperitoneal injection volume of 80 μL, while the control group received the same volume of saline. After each week of dosing, 20-35 mice were randomly removed and weighed, and the average weight was used as an important basis for the next week's dosing.
[0062] 2. Behavioral testing
[0063] 2.1. Short-term learning and memory
[0064] 2.1.1.Y maze
[0065] The Y-maze apparatus used in this experiment had three interconnected arms with an angle of 120 degrees between them. All three arms were identical in size, measuring 29 cm × 8 cm × 15 cm. Different patterns were applied to the inside of the arms as visual markers for the mice, and the arms were designated as the start arm, novel arm, and other arms. The experimental procedure consisted of two phases: an acclimation phase and a test phase, with a 1-2 hour interval between the two phases. During the acclimation phase, the novel arm was separated by a barrier, and the mice could only move freely within the start arm and the other arms. Each mouse acclimated for 5 minutes. After 1-2 hours, the test phase opened the novel arm, allowing the mice to move freely within the three arms. Each mouse was tested for 5 minutes. Topscan software was used to record the time and number of times the mice entered the novel arm in real time. After each experiment, the experimental apparatus was cleaned with 75% alcohol to remove mouse odor.
[0066] 2.1.2. Novel Object Recognition
[0067] Before testing this device, mice were petted daily to avoid irritation during handling. In the first phase (familiarization phase), two identical objects (A and B, ensuring they were odorless and could not be pushed) were placed in the device, 10 cm from the two walls. The mice were placed equidistant from the objects with their backs facing them. A camera and software were used to record the amount of time the mice spent exploring each object (exploration was counted as touching the object with their mouth or nose or moving within 2-3 cm of the object). Over a 5-minute period (many experiments have shown that after 2 minutes of familiarization, animals already have a strong preference for novelty, and of course, this preference becomes even more pronounced after 3 minutes of familiarization), the number, duration, and distance of exploration of each object were measured. In the second phase (test phase), one hour after the completion of phase 1, one of the two identical objects was replaced with a different object (AC or BC). The mice were again placed equidistant from the objects with their backs facing them for 5 minutes. The number, duration, and distance of exploration of the new and old objects by mice—that is, the number, duration, and distance of activity around the new and old objects—tests the mice's cognitive abilities. Mice with poor cognitive abilities will explore the new and old objects in the same way; mice with normal cognitive abilities will explore the new objects more frequently than the old ones. The recognition index (RI) is calculated as: RI = new object / (new object + old object) × 100%.
[0068] 2.2. Conditioned fear memory
[0069] On the first day of this experiment, mice were placed in a box (with copper bars at the bottom and electricity). After acclimation for 3 minutes, the mice were allowed to stay in the box for another 6 minutes. During this period, a single frequency sound stimulation (1.0KHZ, 70db, 30s) and an inescapable foot shock (0.8mA, 2s) were given every 2 minutes for a total of three times. The total time of sound and electric shock-induced freezing behavior in the mice within 6 minutes was recorded, and then they were returned to the breeding cage. After each experiment, the bottom of the box was wiped with 75% alcohol. After 24 hours, the mice with established conditioned fear were placed in the original box and immediately given sound stimulation of the same intensity (1.0KHZ, 70db, 30s). The sound-induced freezing behavior of the mice was recorded within 3 minutes. Freezing behavior is defined as the absence of other movement behaviors except breathing. The percentage of freezing time induced by environment and sound is recorded.
[0070] 2.3. Social Behavior
[0071] 2.3.1. Social preference stage
[0072] Before the experiment began, mice were placed in the behavioral testing room to acclimate for 0.5 h. The rectangular box being tested was divided into three equal areas: Empty, Center, and Stranger 1. Mice of the same sex were placed in the metal cage in the Stranger 1 area, while the metal cages in the other box were left empty. The test mice were placed in the center box, allowing them to move freely in all three boxes for 5 min. The relevant parameters were immediately photographed and recorded: the duration of entry into each box; when the mouse's head and all four paws entered a box, it was considered to be in that box.
[0073] 2.3.2. Social Memory Stage
[0074] In the social memory phase of the experiment, a stranger mouse of the same species (Stranger 2) was placed in another metal cage, and then the time spent by the test mouse in the Stranger 1 and Stranger 2 areas was recorded for 5 minutes.
[0075] 3. Brain Tissue Collection and Slice Preparation
[0076] 3.1. Obtain materials
[0077] Mice were sampled promptly after behavioral testing. Blood was collected from the eyeball after anesthesia. Saline was perfused through the left ventricle of the heart until the liver turned a khaki color. The solution was then replaced with 4% paraformaldehyde and perfused for 5 minutes. The brain was then fixed in 4% paraformaldehyde overnight at 4°C. The brain tissue, including the hippocampus and cortex, was excised and dehydrated using a sucrose gradient.
[0078] 3.2. Frozen Section Preparation
[0079] The brain tissue embedded in OCT resin was sliced into serial sagittal sections with a thickness of 20 μm using a Leica cryostat. The sections were collected in PBS for immunofluorescence staining and Aβ histopathological analysis.
[0080] 4. Immunofluorescence Staining
[0081] Sections were blocked with 10% goat serum in PBS at room temperature for 1 hour. The blocking solution was discarded, and antibodies against mouse 6E10, chicken glial fibrillary acidic protein (GFAP), and rabbit calcium binding adapter molecule 1 (Iba1) were added and incubated overnight at 4°C. The primary antibodies were removed the next day, and the sections were washed three times with PBS for 5 minutes each. Secondary antibodies of the corresponding species (goat anti-chicken IgG-488; donkey anti-rabbit IgG-488; and donkey anti-mouse IgG-647) were added and incubated at room temperature in the dark for 1 hour. The secondary antibodies were discarded, and the sections were washed three times with PBS for 5 minutes each. The sections were mounted with anti-quencher and photographed under a fluorescence microscope.
[0082] 5. Thioflavin S staining
[0083] Thioflavin S can label Aβ core plaques on brain slices. Add 1% thioflavin solution to the slices, incubate at room temperature for 5 minutes, rinse with running water for 1 minute, separate with 70% alcohol for 30 seconds, then seal with anti-fluorescence quencher and photograph under a fluorescence microscope.
[0084] 6. Image Analysis
[0085] Immunohistochemically stained tissue sections were photographed using a Leica microscope, and grayscale threshold analysis was performed using Image J software to calculate the percentage of positive areas for GFAP, Iba1, 6E10, and thioflavin. There were 4-5 mice in each group, and 3 sections were selected for each mouse. The average value was taken as the statistical result for the group.
[0086] 7. Enzyme-linked immunosorbent assay (ELISA)
[0087] 7.1. Obtaining materials
[0088] After anesthesia, mice were decapitated and the skin of the neck and head was peeled off to expose the skull. The skull was cut open along the sagittal suture, and the brain tissue was removed after separation. The cortical and hippocampal tissues were placed in separately labeled centrifuge tubes, quickly frozen in liquid nitrogen, and stored in a -80°C freezer.
[0089] Sample preparation
[0090] Remove approximately 10-20 mg of prefrontal cortex and hippocampal tissue from an ice box, weigh it into a 1.5 mL centrifuge tube, and add RIPA lysis buffer at a mass-to-volume ratio of 1:10. Return the remaining tissue to the original tube and snap-freeze it in liquid nitrogen. Add two steel balls to the centrifuge tube, balance it in a homogenizer, and homogenize and lyse it. Shake on ice for 30 minutes. Remove the steel balls, centrifuge at 12,000 rpm, 4°C, for 15 minutes, aspirate the supernatant thoroughly, and transfer it to a new 1.5 mL centrifuge tube. Quantify protein concentration using a protein quantification method.
[0091] ELISA
[0092] Dilute the sample to the appropriate concentration in diluent and add the diluted sample to the enzyme-labeled reaction wells for testing three pro-inflammatory markers: interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α). At least two wells were prepared for each sample, with 45 μL of standard and sample per well. Then, 50 μL of biotinylated antibody working solution was added to the sample and standard wells. The reaction plate was sealed with sealing paper and incubated at room temperature for 2 hours (using a microplate shaker at 300 rpm). Enzyme-binding substrate was prepared 30 minutes in advance and stored at room temperature in the dark. After discarding the liquid from the wells, pat dry on absorbent paper. Wash the wells five times. Aspirate the reaction solution from the wells, add the wash solution, and incubate for 2 minutes with gentle agitation. Add 100 μL of enzyme-binding substrate working solution to each well, except for the blank well, and incubate at room temperature for 1 hour (using a microplate shaker at 300 rpm). After discarding the liquid from the wells, pat dry on absorbent paper. Wash five times. Add 100 μL of chromogenic substrate working solution to each well except the blank well and incubate at room temperature in the dark for 15 minutes. Terminate the reaction by adding 100 μL of stop solution to each well except the blank well. Measure the results within 20 minutes. Measure the absorbance of the standard and test wells at 450 nm. Draw a standard curve based on the standard wells and known concentrations. Calculate the actual concentration of the test wells from the standard curve. Finally, calculate the target protein mass per milligram of brain tissue based on the protein concentration.
[0093] 2. Research Results
[0094] 1. Effects of different doses of levofloxacin on memory behavior of APP / PS1 mice
[0095] Short-term memory was assessed using a Y-maze. Results showed that compared with the control group, the time spent in the novel arm of APP / PS1 mice increased with increasing doses of levofloxacin, but the difference was not significant. No significant increase in the number of entries into the novel arm was observed after administration of levofloxacin (5-40 U / kg) (Figure 1A-B). Short-term memory in the novel object recognition test was assessed using a novel object recognition test. Results showed that the novel object recognition index of APP / PS1 mice increased with increasing doses of levofloxacin (5-40 U / kg), with a significant increase in the novel object recognition index of mice in the 40 U / kg group (Figure 1C). Conditioned fear memory was assessed using a fear conditioning test. Results showed that the percentage of freezing time in APP / PS1 mice did not decrease significantly with increasing doses of levofloxacin (5-40 U / kg) compared with the control group (Figure 1D). The three-chamber test was used to evaluate the sociability of each group of mice. The results showed that in the social preference phase, mice in the 5-10 U / kg group showed no significant preference for mice of the same sex, while mice in the 20-40 U / kg group showed a social preference, although there was no significant difference (Figure 1E) (normal WT mice showed a preference for mice of the same sex); in the social memory phase, the groups at all doses showed no significant preference for unfamiliar mice, suggesting that sociability did not improve significantly (Figure 1F). These results are also shown in Table 1.
[0096]
[0097] 2. Effects of different doses of Lizaitin on the alleviation of Aβ plaque deposition in APP / PS1 mice
[0098] Thioflavin staining was used to assess Aβ deposition in each group of mice. The results showed that compared with the control group, increasing doses of Lizaixide (5-40 U / kg) reduced Aβ plaques in the hippocampus and cortex of mice, with a significant reduction in Aβ plaques in the 40 U / kg group (Figures 2A-C). 6E10 staining revealed significant reductions in hippocampal Aβ plaques in the 10, 20, and 40 U / kg groups, with a significant reduction in cortical Aβ plaques in the 40 U / kg group (Figures 2D-F). Thioflavin binds to mature Aβ plaques, while 6E10 binds to amino acid residues 1-16 of the Aβ protein. Therefore, thioflavin primarily detects larger, fibrillar Aβ plaques, while 6E10 can detect both larger and smaller plaques, making 6E10 staining more sensitive than thioflavin staining. The results are also shown in Table 2.
[0099] Table 2 Effects of different doses of Lizaix on Aβ deposition in APP / PS1 mice
[0100]
[0101] *p<0.05vs. control group.
[0102] 3. Effects of different doses of Lizaitin on the activation of glial cells surrounding Aβ plaques in the cortex of APP / PS1 mice
[0103] 6E10, GFAP, and Iba1 co-labeling were used to evaluate the activation of astrocytes (GFAP staining) and microglia (Iba1 staining) surrounding Aβ plaques in the cortex of APP / PS1 mice. The results showed that compared with the control group, administration of 5-40 U / kg of Lisitol showed a trend of decreasing astrocyte activation in the cerebral cortex and hippocampus of mice, with no significant difference. However, administration of Lisitol (40 U / kg) significantly reduced the activation of microglia in the cerebral cortex and hippocampus of mice (Figures 3 and 4). The results are also shown in Tables 3 and 4.
[0104] Table 3 and Table 4 Effects of different doses of Lizaitin on the activation of glial cells surrounding Aβ plaques in the cortex and hippocampus of APP / PS1 mice
[0105]
[0106]
[0107] *p<0.05vs. control group.
[0108] 4. Effects of different doses of Lizaishi on reducing the levels of inflammatory factors in the cortex and hippocampus of APP / PS1 mice
[0109] Enzyme-linked immunosorbent assays were used to evaluate the expression of inflammatory factors IL-1β, IL-6, and TNF-α in the cerebral cortex of each group of mice. The results showed that compared with the control group, the 40 U / kg Lizaishi group significantly reduced the expression of inflammatory factors IL-1β, IL-6, and TNF-α in the cerebral cortex of APP / PS1 mice (Figures 5A-C). However, compared with the control group, Lizaishi in different groups did not significantly improve the expression of inflammatory factors in the hippocampus of APP / PS1 mice (Figures 5D-F). The results are also shown in Table 5.
[0110] 3. Conclusion
[0111] Lisitol significantly alleviated short-term cognitive impairment in AD model mice at 40 U / kg. Furthermore, Lisitol reduced Aβ burden and microglial inflammatory responses at 40 U / kg. Lisitol's neuroprotective effect on short-term cognitive impairment in AD model mice may be achieved by reducing Aβ burden and microglial inflammatory responses.
[0112]
Claims
1. Use of an extract from rabbit skin inflamed by vaccinia virus in the preparation of a medicament for preventing or treating Alzheimer's disease in a patient.
2. The method of claim 1, wherein the drug is used to protect brain nerve function or alleviate brain nerve function damage in patients with Alzheimer's disease.
3. The method of claim 1, wherein the prevention or treatment is achieved by alleviating or reducing brain β-amyloid plaque deposition, alleviating or reducing glial cell inflammatory response, or alleviating or reducing the expression or level of inflammatory factors.
4. Use of an extract from rabbit skin inflamed by vaccinia virus in the preparation of a medicament for alleviating or reducing the deposition of β-amyloid plaques in the brain of a patient with Alzheimer's disease.
5. Use of a vaccinia virus-inflamed rabbit skin extract in the preparation of a medicament for alleviating or reducing glial cell inflammatory response in the brain of a patient with Alzheimer's disease.
6. The use according to claim 3 or 5, wherein the glial cells are selected from microglia or astrocytes.
7. Use of an extract from rabbit skin inflamed by vaccinia virus in the preparation of a medicament for alleviating or reducing the expression or level of inflammatory factors in the brain of a patient suffering from Alzheimer's disease.
8. The use according to claim 3 or 7, wherein the inflammatory factor is selected from IL-1β, IL-6 or TNF-α.
9. Use of a vaccinia virus-inflamed rabbit skin extract in the preparation of a medicament for improving, enhancing or restoring cognitive functions or cognitive abilities, preferably including perception, logical thinking, memory, language, learning, emotional control, social skills or attention, in patients with Alzheimer's disease.
10. The use according to any one of claims 1 to 9, wherein the extract of rabbit skin inflamed by vaccinia virus is Lizaitin.
11. The use according to any one of claims 1 to 10, wherein the extract of vaccinia virus-inflamed rabbit skin is formulated into an oral preparation or an injection, preferably an intramuscular injection or an intravenous injection.
12. The use according to any one of claims 1 to 11, wherein the patient is a human, preferably an elderly person.
13. The use according to any one of claims 1 to 12, wherein the vaccinia virus-inflamed rabbit skin extract is administered to the patient in an amount of 0.05 U / kg to 50 U / kg, preferably 0.1 U / kg to 10 U / kg, more preferably 0.5 U / kg to 5 U / kg.
14. The use according to any one of claims 1 to 13, wherein the medicament comprises 3 U to 3000 U, preferably 6 U to 600 U, more preferably 30 U to 300 U of the vaccinia virus-induced inflamed rabbit skin extract.
